

# **Plasma Protein Therapeutics Market based on Type (Coagulation Factors, Immunoglobulins, Albumins, and C1 esterase Inhibitors), Application (Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic, Purpura, Secondary Immunodeficiency, Hereditary Angioedema, and Others) and Geography – Global Forecast to 2027**

<https://marketpublishers.com/r/PFF434C6CE96EN.html>

Date: July 2021

Pages: 128

Price: US\$ 4,000.00 (Single User License)

ID: PFF434C6CE96EN

## **Abstracts**

Plasma is the protein-rich fluid present in the blood, which has a vital role in clotting and providing immunity against diseases. They can be utilized in medical therapies, such as autoimmune, immune deficiencies, neurological and bleeding disorders when proteins are separated from plasma. By restoring the deficient or lost proteins in plasma, these protein therapies cure well-defined medical conditions. To treat life-threatening, chronic, and genetic diseases, plasma protein therapeutics are used, consisting of biological medicines, either infused or injected. The Plasma Protein Therapeutics Market is estimated to grow at the rate of 8.98% CAGR by 2027. The key propellant factor for the plasma protein therapeutics market growth is the rising advents of new plasma-derived therapies. Further, the increasing number of life-threatening diseases such as immune or neurological systems and other diseases, including rabies, tetanus, hepatitis, A&B, and varicella, are the other key factors projected to compel the plasma protein therapeutics market growth. But, the restricted rules and regulations for handling plasma protein products are impeding the market growth.

Plasma Protein Therapeutics Market based on Type

Coagulation Factors

## Immunoglobulins

Albumins

C1 esterase Inhibitors

## Plasma Protein Therapeutics Market based on Application

Hemophilia

Primary Immunodeficiency Disorder

Idiopathic Thrombocytopenic

Purpura

Secondary Immunodeficiency

Hereditary Angioedema

Others

## Plasma Protein Therapeutics Market based on Geography

North America

Europe

Asia Pacific

Rest of the World

As per the plasma protein therapeutics market by type, the market is divided into Coagulation Factors, Immunoglobulins, Albumins, and C1 esterase Inhibitors. Among them, the albumin segment is projected to obtain a significant share over the forecast period. This is driven by an enhanced diagnosis of hypoalbuminemia disease caused by

liver cirrhosis and hepatitis B. Substantial demand and usage in China, which is the major market for albumin, is expected to boost the market growth further. Patients suffering from medium to severe hemophilia need clotting factor VIII as a preventive or on-demand therapy. The above factors are supporting the segment growth.

As in the plasma protein therapeutics market for application, the applications of the plasma protein therapeutics include Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic, Purpura, Secondary Immunodeficiency, Hereditary Angioedema, and Others. The hemophilia segment is anticipated to hold a substantial share in the market. The substantial share of this segment is attributed to the rising elderly population and the surging number of patients suffering from life-threatening diseases. Also, the shifting lifestyles, such as changing food habits and adopting sedentary lifestyles specifically in the urban areas, lead to diseases.

Further, the geographical plasma protein therapeutics market is categorized into North America, Europe, Asia Pacific, and the rest of the world. The North American region is placed at the top of the market share. This is due to the rising capital income, increasing modern technologies, and introduction of innovative therapies expected to drive the plasma protein therapeutics market growth in the region.

Quality and advancements in plasma therapeutics have been the favorable drivers of the global plasma protein therapeutics market to enhance patients' quality of life and assure donor safety. Plasma obtained through apheresis technology or complete blood donation procedure can either be gathered or bifurcated into plasma protein products which comprise one or more purified plasma protein or transferred directly to patients.

This report provides the few notable vendors of the plasma protein therapeutics market include Takeda Pharmaceutical Company Ltd., China Biologics Products Holdings, Bio Products Laboratory Ltd., ADMA Biologics, Inc., CSL Behring LLC, HEMA Biologics LLC, Biotest AG, Grifols S.A., Kedrion S.P.A., Inc., and Baxter International Ltd.

Hence, plasma protein has increased majorly in medical applications in the past few years. Along with the advancements in technology, the procedure of separating the protein from plasma has become highly cost-efficient and cost-saving, which has increased the importance of plasma protein therapies.

This report offers an overall analysis of the present and future market trends and dynamics in the plasma protein therapeutics market.

Geographically, the market report analyzes the regions such as North America, Europe, Asia Pacific, and the rest of the world.

This report includes a comprehensive quantitative analysis of the present market and projections, which helps to identify the emerging market opportunities.

This report also includes the significant plasma protein therapeutics market players and their dynamic strategies, expansions, mergers, acquisitions, and new product launches.

## Contents

### 1. EXECUTIVE SUMMARY

### 2. INDUSTRY OUTLOOK

- 2.1. Industry Overview
- 2.2. Industry Trends

### 3. MARKET SNAPSHOT

- 3.1. Market Definition
- 3.2. Market Outlook
  - 3.2.1. Porter Five Forces
- 3.3. Related Markets

### 4. MARKET CHARACTERISTICS

- 4.1. Market Overview
- 4.2. Market Segmentation
- 4.3. Market Dynamics
  - 4.3.1. Drivers
  - 4.3.2. Restraints
  - 4.3.3. Opportunities
- 4.4. DRO - Impact Analysis

### 5. TYPE: MARKET SIZE & ANALYSIS

- 5.1. Overview
- 5.2. Coagulation Factors
- 5.3. Immunoglobulins
- 5.4. Albumins
- 5.5. C1 esterase Inhibitors

### 6. APPLICATION: MARKET SIZE & ANALYSIS

- 6.1. Overview
- 6.2. Hemophilia
- 6.3. Primary Immunodeficiency Disorder

- 6.4. Idiopathic Thrombocytopenic
- 6.5. Purpura
- 6.6. Secondary Immunodeficiency
- 6.7. Hereditary Angioedema
- 6.8. Others

## **7. GEOGRAPHY: MARKET SIZE & ANALYSIS**

- 7.1. Overview
- 7.2. North America
- 7.3. Europe
- 7.4. Asia Pacific
- 7.5. Rest of the World

## **8. COMPETITIVE LANDSCAPE**

- 8.1. Competitor Comparison Analysis
- 8.2. Market Developments
  - 8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
  - 8.2.2. Product Launches and execution

## **9. VENDOR PROFILES**

- 9.1. Takeda Pharmaceutical Company Ltd.
  - 9.1.1. Overview
  - 9.1.2. Financial Overview
  - 9.1.3. Product Offerings
  - 9.1.4. Developments
  - 9.1.5. Business Strategy
- 9.2. China Biologics Products Holdings
  - 9.2.1. Overview
  - 9.2.2. Financial Overview
  - 9.2.3. Product Offerings
  - 9.2.4. Developments
  - 9.2.5. Business Strategy
- 9.3. Bio Products Laboratory Ltd.
  - 9.3.1. Overview
  - 9.3.2. Financial Overview
  - 9.3.3. Product Offerings

- 9.3.4. Developments
- 9.3.5. Business Strategy
- 9.4. ADMA Biologics, Inc.
  - 9.4.1. Overview
  - 9.4.2. Financial Overview
  - 9.4.3. Product Offerings
  - 9.4.4. Developments
  - 9.4.5. Business Strategy
- 9.5. CSL Behring LLC
  - 9.5.1. Overview
  - 9.5.2. Financial Overview
  - 9.5.3. Product Offerings
  - 9.5.4. Developments
  - 9.5.5. Business Strategy
- 9.6. HEMA Biologics LLC
  - 9.6.1. Overview
  - 9.6.2. Financial Overview
  - 9.6.3. Product Offerings
  - 9.6.4. Developments
  - 9.6.5. Business Strategy
- 9.7. Biotest AG
  - 9.7.1. Overview
  - 9.7.2. Financial Overview
  - 9.7.3. Product Offerings
  - 9.7.4. Developments
  - 9.7.5. Business Strategy
- 9.8. Grifols S.A.
  - 9.8.1. Overview
  - 9.8.2. Financial Overview
  - 9.8.3. Product Offerings
  - 9.8.4. Developments
  - 9.8.5. Business Strategy
- 9.9. Kedrion S.P.A., Inc.
  - 9.9.1. Overview
  - 9.9.2. Financial Overview
  - 9.9.3. Product Offerings
  - 9.9.4. Developments
  - 9.9.5. Business Strategy
- 9.10. Baxter International Ltd.

- 9.10.1. Overview
- 9.10.2. Financial Overview
- 9.10.3. Product Offerings
- 9.10.4. Developments
- 9.10.5. Business Strategy

## **10. ANALYST OPINION**

## **11. ANNEXURE**

- 11.1. Report Scope
- 11.2. Market Definitions
- 11.3. Research Methodology
  - 11.3.1. Data Collation and In-house Estimation
  - 11.3.2. Market Triangulation
  - 11.3.3. Forecasting
- 11.4. Report Assumptions
- 11.5. Declarations
- 11.6. Stakeholders
- 11.7. Abbreviations



## List Of Tables

### LIST OF TABLES

TABLE 1. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 2. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR COAGULATION FACTORS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR IMMUNOGLOBULINS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR ALBUMINS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR C1 ESTERASE INHIBITORS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR HEMOPHILIA, 2021-2027 (USD BILLION)

TABLE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR PRIMARY IMMUNODEFICIENCY DISORDER, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR IDIOPATHIC THROMBOCYTOPENIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR PURPURA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR SECONDARY IMMUNODEFICIENCY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR HEREDITARY ANGIOEDEMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 14. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 15. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 16. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 17. U.S PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 18. U.S PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 19. CANADA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 20. CANADA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 21. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 22. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 23. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, APPLICATION, 2021-2027 (USD BILLION)

TABLE 24. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 25. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 26. U.K PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 27. U.K PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 28. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 29. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 30. ITALY PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 31. ITALY PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 32. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 33. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 34. ROE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 35. ROE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 36. ASIA PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 37. ASIA PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY

TYPE, 2021-2027 (USD BILLION)

TABLE 38. ASIA PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 39. CHINA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 40. CHINA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 41. INDIA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 42. INDIA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 43. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 44. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 45. REST OF APAC PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 46. REST OF APAC PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 47. REST OF WORLD PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 48. REST OF WORLD PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

TABLE 49. TAKEDA PHARMACEUTICAL COMPANY LTD: FINANCIALS

TABLE 50. TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCTS & SERVICES

TABLE 51. TAKEDA PHARMACEUTICAL COMPANY LTD: RECENT DEVELOPMENTS

TABLE 52. CHINA BIOLOGICS PRODUCTS HOLDINGS: FINANCIALS

TABLE 53. CHINA BIOLOGICS PRODUCTS HOLDINGS: PRODUCTS & SERVICES

TABLE 54. CHINA BIOLOGICS PRODUCTS HOLDINGS: RECENT DEVELOPMENTS

TABLE 55. BIO PRODUCTS LABORATORY LTD: FINANCIALS

TABLE 56. BIO PRODUCTS LABORATORY LTD: PRODUCTS & SERVICES

TABLE 57. BIO PRODUCTS LABORATORY LTD: RECENT DEVELOPMENTS

TABLE 58. ADMA BIOLOGICS, INC: FINANCIALS

TABLE 59. ADMA BIOLOGICS, INC: PRODUCTS & SERVICES

TABLE 60. ADMA BIOLOGICS, INC: RECENT DEVELOPMENTS

TABLE 61. CSL BEHRING LLC: FINANCIALS

TABLE 62. CSL BEHRING LLC: PRODUCTS & SERVICES

TABLE 63. CSL BEHRING LLC: RECENT DEVELOPMENTS

|   |
|---|
| TABLE 64. HEMA BIOLOGICS LLC: FINANCIALS                |
| TABLE 65. HEMA BIOLOGICS LLC: PRODUCTS & SERVICES       |
| TABLE 66. HEMA BIOLOGICS LLC: RECENT DEVELOPMENTS       |
| TABLE 67. BIOTEST AG: FINANCIALS                        |
| TABLE 68. BIOTEST AG: PRODUCTS & SERVICES               |
| TABLE 69. BIOTEST AG: RECENT DEVELOPMENTS               |
| TABLE 70. GRIFOLS S.A.: FINANCIALS                      |
| TABLE 71. GRIFOLS S.A.: PRODUCTS & SERVICES             |
| TABLE 72. GRIFOLS S.A.: RECENT DEVELOPMENTS             |
| TABLE 73. KEDRION S.P.A., INC: FINANCIALS               |
| TABLE 74. KEDRION S.P.A., INC: PRODUCTS & SERVICES      |
| TABLE 75. KEDRION S.P.A., INC: RECENT DEVELOPMENTS      |
| TABLE 76. BAXTER INTERNATIONAL LTD: FINANCIALS          |
| TABLE 77. BAXTER INTERNATIONAL LTD: PRODUCTS & SERVICES |
| TABLE 78. BAXTER INTERNATIONAL LTD: RECENT DEVELOPMENTS |

## List Of Figures

### LIST OF FIGURES

CHART. 1. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 2. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR COAGULATION FACTORS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR IMMUNOGLOBULINS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR ALBUMINS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR C1 ESTERASE INHIBITORS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR HEMOPHILIA, 2021-2027 (USD BILLION)

CHART. 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR PRIMARY IMMUNODEFICIENCY DISORDER, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR IDIOPATHIC THROMBOCYTOPENIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR PURPURA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR SECONDARY IMMUNODEFICIENCY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR HEREDITARY ANGIOEDEMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 14. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

CHART. 15. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 16. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 17. U.S PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 18. U.S PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 19. CANADA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 20. CANADA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 21. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

CHART. 22. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 23. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, APPLICATION, 2021-2027 (USD BILLION)

CHART. 24. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 25. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 26. U.K PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 27. U.K PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 28. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 29. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 30. ITALY PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 31. ITALY PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 32. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 33. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 34. ROE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 35. ROE PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 36. ASIA PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

CHART. 37. ASIA PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET VALUE,

BY TYPE, 2021-2027 (USD BILLION)

CHART. 38. ASIA PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET VALUE,  
BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 39. CHINA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE,  
2021-2027 (USD BILLION)

CHART. 40. CHINA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY  
APPLICATION, 2021-2027 (USD BILLION)

CHART. 41. INDIA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY TYPE,  
2021-2027 (USD BILLION)

CHART. 42. INDIA PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY  
APPLICATION, 2021-2027 (USD BILLION)

CHART. 43. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY  
TYPE, 2021-2027 (USD BILLION)

CHART. 44. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET VALUE, BY  
APPLICATION, 2021-2027 (USD BILLION)

CHART. 45. REST OF APAC PLASMA PROTEIN THERAPEUTICS MARKET VALUE,  
BY TYPE, 2021-2027 (USD BILLION)

CHART. 46. REST OF APAC PLASMA PROTEIN THERAPEUTICS MARKET VALUE,  
BY APPLICATION, 2021-2027 (USD BILLION)

CHART. 47. REST OF WORLD PLASMA PROTEIN THERAPEUTICS MARKET  
VALUE, BY TYPE, 2021-2027 (USD BILLION)

CHART. 48. REST OF WORLD PLASMA PROTEIN THERAPEUTICS MARKET  
VALUE, BY APPLICATION, 2021-2027 (USD BILLION)



## I would like to order

Product name: Plasma Protein Therapeutics Market based on Type (Coagulation Factors, Immunoglobulins, Albumins, and C1 esterase Inhibitors), Application (Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic, Purpura, Secondary Immunodeficiency, Hereditary Angioedema, and Others) and Geography – Global Forecast to 2027

Product link: <https://marketpublishers.com/r/PFF434C6CE96EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFF434C6CE96EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>



To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970